{"id":"W4249577962","doi":"10.1158/1538-7445.sabcs19-ot2-04-04","title":"Abstract OT2-04-04: Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase 2 trial","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Pembrolizumab; Trastuzumab; Pertuzumab; Internal medicine; Breast cancer; Oncology; Neoadjuvant therapy; Clinical endpoint; Randomized controlled trial; Cancer; Metastatic breast cancer; Gastroenterology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001764107,0.00181104,0.001958744,0.0003267534,0.0004734146,0.00134009,0.0009504487,0.001616297,0.009286596],"category_scores_gemma":[0.0009284334,0.0006217723,0.001202845,0.0003818987,0.001286051,0.001352043,0.0004536294,0.002854559,0.001471215],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009497133,"about_ca_system_score_gemma":0.001429091,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006988025,"about_ca_topic_score_gemma":0.001483658,"domain_scores_codex":[0.9994826,0.0002765566,0.000027488,0.00007979869,0.00003556831,0.00009779164],"domain_scores_gemma":[0.9994091,0.00009366559,0.00012984,0.00005689184,0.00003795959,0.0002725007],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9679884,0.01378802,0.0007359296,0.0003079122,0.0003210011,0.00003685003,0.00002862328,0.0002387473,0.003868211,0.00009811253,0.001194732,0.01139344],"study_design_scores_gemma":[0.8970507,0.09982234,0.001128949,0.00002287412,0.0002033026,0.00003615356,0.00001680401,0.0002489707,0.0005475729,0.0001314436,0.0007818653,0.000009015097],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842025,0.002087189,0.0006385917,0.001108466,0.0003878792,0.006062923,0.002481094,0.0001523345,0.002878896],"genre_scores_gemma":[0.9739116,0.002100684,0.00207162,0.00185585,0.000702202,0.008894753,0.003098582,0.00003948905,0.007325239],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009286596,"threshold_uncertainty_score":0.03106672,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1636923583760914,"score_gpt":0.4642077291462534,"score_spread":0.300515370770162,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}